Combination therapy before and after liver cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three treatments (HAIC, camrelizumab, and apatinib) given before and after surgery for early-stage liver cancer that has high risk of coming back. The goal is to reduce the chance of cancer recurrence and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 years old
- Confirmed hepatocellular carcinoma (liver cancer) at early-to-intermediate stage that can be removed by surgery
- Cancer has high-risk features (large tumor, aggressive cells under microscope, or very high tumor marker levels)
- Good overall health (ECOG score 0–1) with normal or near-normal liver, kidney, and heart function
- No prior cancer treatment (surgery, chemotherapy, or immunotherapy)
- Normal blood counts and liver enzymes within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This study tests whether combining two immunotherapy drugs (sintilimab and ipilimumab) with standard procedures to block or destroy the tumor's blood supply can help keep liver cancer from returning after surgery. It is for people whose liver cancer can be removed but has a higher risk of coming back.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.